Drugs / ABO1020
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT05636319 | Nov 2022 → Apr 2023 | COVID-19 | Suzhou Abogen Biosciences Co., Ltd. | Unknown | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABO1020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05636319 ↗ |
| Modality | Messenger RNA (mRNA) | “ABO1020 is a monovalent COVID-19 mRNA vaccine.” PMID 39025066 ↗ Jul 2024 |
| Route | Intramuscular | “Intramuscularly inject 15 μg of ABO1020 into lateral deltoid region of the upper arm of subjects on D0 and D28, respectively.” NCT05636319 ↗ |